title: Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts.
abstract: This pilot study, a retrospective case series analysis, examined the feasibility and effectiveness of treating alcohol dependence with extended-release naltrexone (XR-NTX) in the drug court setting. In two Michigan courts and in one Missouri court, 32 clients were treated with XR-NTX and were matched with 32 clients with standard care in an open-label, voluntary recruitment design. Treatment with XR-NTX was associated with relative risk reductions (RRRs; p = ns) of 57% fewer missed drug court sessions, a 35% reduction in the monthly ratio of positive drug and alcohol tests to total tests, and 35% fewer individuals with greater than 25% overall positive alcohol or drug tests. In the principal end-point analysis of annualized number of new arrests, 26% of standard-care clients were rearrested versus 8% on XR-NTX (RRR = 69%; p < .05). Treatment with XR-NTX appeared to be feasible and was associated with a consistently large treatment effect across multiple outcomes relevant to the drug court setting.
authors.affiliation: Northwest Professional Consortium, Inc, Portland, OR 97239, USA. finigan@npcresearch.com
authors.forename: Michael W
authors.initials: MW
authors.lastname: Finigan
authors.forename: Tamara
authors.initials: T
authors.lastname: Perkins
authors.forename: Phyllis
authors.initials: P
authors.lastname: Zold-Kilbourn
authors.forename: Joseph
authors.initials: J
authors.lastname: Parks
authors.forename: Mark
authors.initials: M
authors.lastname: Stringer
mesh_terms: D000328:Adult; D000428:Alcohol Drinking / Q000331:legislation & jurisprudence* / Q000517:prevention & control; D000437:Alcoholism / Q000188:drug therapy*; D001334:Automobile Driving / Q000331:legislation & jurisprudence; D003416:Criminal Law; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008824:Michigan; D008923:Missouri; D009271:Naltrexone / Q000008:administration & dosage / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D012189:Retrospective Studies; D015813:Substance Abuse Detection; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000517:prevention & control*; D013695:Temperance
chemical_list: D003692:Delayed-Action Preparations; D009292:Narcotic Antagonists; D009271:Naltrexone